Denosumab administration, a RANKL inhibitor, seems a rational treatment strategy in LCH in order to enhance further endogenous osteoprotegerin action and interrupt the lesional immunological process if RANKL related. This evidence concerns the gene TNFSF11 and Langerhans cell histiocytosis.